Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a study of BMS-986523 alone and in combination for KRAS-altered advanced solid tumors
2025-523547-35-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Countries
- 3
01
Overview
Phase 2, open-label trial of BMS-986523 in Non-hematologic malignancy, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability. Planned start Apr 2026; status: authorised.
02
Drugs
BMS-986523
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-523547-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523547-35-00.